BRIEF Bendamustine and Rituximab In Elderly Follicular
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the complete response rate after a short induction
treatment with rituximab (375mg/m2)and bendamustine (90mg/m2)in In Elderly (≥ 60 years old)
patients with untreated Follicular lymphoma, with an intermediate or high FLIPI score and
without high tumor burden.
This short induction is followed by a rituximab (375mg/m2)maintenance/ Induction
schedule:Rituximab+Bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8,
Rituximab on Day 15, rituximab on day 22, Bendamustine on Day 29, Bendamustine on Day 30
Maintenance schedule: 12 infusions of rituximab, each 8 weeks